Overview
Spherix’s coverage of the plaque psoriasis market focuses on the shift from long standing biologic treatments to alternative mechanisms of action, highlighting in-class competition.
Services Available
Trending market evolution
-
Plaque Psoriasis (US) - quarterly, n=100
-
Plaque Psoriasis (EU) - semiannual, n=250
Exploring the patient journey
-
Biologic/Small Molecule New Starts in PSO (US) - annual, n=1,000 patient charts
-
Biologic/Small Molecule Switching in PSO (US) - annual, n=1,000 patient charts
-
Biologic/Small Molecule Switching in PSO (EU) - annual, n=1,250 patient charts
Benchmarking new brand performance
-
Bimekizumab (UCB) in Psoriasis (US)*
*Pending approvals and launch